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Recent Strategies to Overcome the
Hyperacute Rejection in Pig to Human
Xenotransplantation
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Budapest, Hungary
Due to the ever increasing shortage ofsuitable human donors, alternative strategies are sought to
moderate the current discrepancy between the number ofexecutable and required transplantations.
Xenotransplantation (i.e., the transplantation oforgans [tissues or cells] between different species)
appears to be a reasonable solution. However, various problems (immunological, physiological,
infectious-microbiological, ethical-juridicial) seem to be associated with xenotransplantation. One
ofthe mostformidable barriers to xenotransplantation is thephenomenon ofhyperacute rejection
that may lead to the destruction ofthe transplanted vascularized organ in afew minutes to hours.
In the pathogenesis ofhyperacute rejection, xenoreactive antibodies and the complement system
appear to be ofprimary importance. Various methods can be applied to prevent hyperacute rejec-
tion; both the recipientandthe donorcan be treated. In this briefreview, the authorattempts topre-
sent a synopsis ofthepossible therapeutical interventions toprevent hyperacute rejection..
INTRODUCTION
Based on the ever increasing shortage
of suitable human donor organs, alterna-
tive solutions are sought to diminish the
difference between the number ofrequired
and executable organ transplantations.
Xenotransplantation, i.e., the transplan-
tation of organs (tissues or cells) between
different species seems to be a possible
solution, since it could provide unlimited
resources of transplantable organs.
Although the nonhuman primates would
appear to be the ideal donor animals for
human xenotransplantation because of
both immunological and physiological
similarities, there are several problems
associated with their possible application:
the majority of them belong to the group
ofendangered species, they are difficult to
breed, their aseptic housing is not solved,
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the techniques for their genetic manipula-
tion have not yet been developed, and
there are considerable infectious-microbi-
ological and ethical concerns that do not
favor their application. Therefore, the
attention ofthe scientific world has turned
toward the pig as a potential organ donor.
The pig has several advantages: it is avail-
able in large numbers, easy to breed, it can
be housed under aseptic conditions, the
techniques for its genetic manipulation are
known, and considering that it is con-
sumed worldwide, the ethical concerns
would be minor compared to that of non-
human primates. Nevertheless, since the
evolutionary distance between the swine
and the human species is much greater
than the corresponding distance between
humans and the nonhuman primates, the
immunological barriers appear to be more
difficult to overcome in the pig to human
xenotransplantation model than in the pri-
mate to human model [1-4].
Based on the experimental findings
using pigs as donors and nonhuman pri-
mates, e.g., baboons, as recipients (in a
few cases humans as well), a three-phase
rejection process develops following the
xenotransplantation of a solid, vascular-
ized organ. Within minutes to hours after
transplantation, the so called hyperacute
rejection (HAR)b begins, which can
destroy the organ in quite a short period of
time. If HAR is somehow overcome, a
slower rejection process, the delayed
xenograft rejection (DXR, or acute vascu-
lar rejection) follows, which ruins the
organ in several days. DXR is character-
ized by the progressive infiltration of the
xenograft by natural killer cells and
macrophages, the activation ofendothelial
cells, and by the marked aggregation of
platelets. Xenoreactive antibodies (see
below) that are of primary importance in
the pathogenesis ofHARplay centralroles
in the appearance ofDXR as well. The rel-
evance of DXR from a clinical point of
view is related to the enormous doses of
immunosuppressive medications needed
to inhibit its progression [1-6]. Later, if
somehow DXR could also be averted, the
cell-mediated rejection becomes active.
The cell-mediated rejection seems to bear
the closest resemblance to the rejection
processes of allotransplantation (i.e., the
transplantation of organs between differ-
ent individuals of the same species; this is
the currently applied human transplan-
tation technique) since it is associated with
the structural differences of major histo-
compatibility (MHC) molecules between
different species. As the transplanted
organ must survive the processes of both
HAR and DXR to develop cell-mediated
rejection, the experimental knowledge
about cell-mediated rejection is scarce
when compared to HAR and DXR [1, 4-
6]. The immunological mechanisms
appear to be similar in the pig-to-human
and pig-to-primate xenotransplantation
settings, therefore, the pig-to-primate
xenotranplantation is considered to be a
good model for the pig-to-human
xenotransplantation.
SYNOPSIS OFTHE PROCESSES
OF HYPERACUTE REJECTION
In the pathogenesis of HAR, the so
called xenoreactive antibodies seem to be
of primary significance. The majority of
these xenoreactive antibodies (XNA) react
with antigens of the porcine endothelium
and lead to the destruction ofthe organ via
the activation of the complement cascade.
The main antigen recognized by these
antibodies is the Galal-3Galp1-4GlcNAc
(in the following Galal-3Gal) oligosac-
charide, which is abundantly expressed on
the glycoproteins and glycolipids of
porcine endothelial cells. (The antibodies
recognizing Galal-3Gal are termed anti-
Gal in the following.) Unfortunately the
XNAs naturally occur in high titers in
humans, apes, and Old World monkeys
(Catarrhines). XNAs (both IgG and IgM)Igaz: Overcoming hyperacute rejection in xenotransplantation 331
comprise 1 to 2 percent of the circulating
immunoglobulins in humans [7].
HAR does not occur in the xenotrans-
plantation models of all species combina-
tions. The species combinations where
HAR occurs (e.g., pig to human, pig to
baboon) are called discordant, whereas
those where HAR does not appear are
termed concordant (e.g., mouse to rat,
baboon to human). The difference between
discordant and concordant species combi-
nations is associated with the presence or
absence of XNAs in the recipient's blood.
The majority of animals studied to date
express the Galcxl-3Gal epitope on the
endothelial cells, whereas humans and
nonhuman primates do not [1, 5]. The
absence of Galcl-3Gal expression in
humans and primates is related to defects
of the al,3-galactosyl-transferase gene
that catalyzes the assembly of the Galal-
3Gal molecule in other animals. Since
similar galactosyl structures are found on
bacteria (and otherpathogens) as well, it is
assumed that the appearance and high titer
ofthese XNAs may be related to the more
effective defense against certain
pathogens, mainly bacteria [8]. The natur-
al XNAs are absent at birth, but develop in
a few weeks or months thereafter [7], pos-
sibly in association with the bacterial col-
onization of the gastrointestinal tract.
Therefore the presence of XNAs is pre-
sumed to be advantageous forthe immuni-
ty against bacteria, but deleterious in such
an abnormal, "man-made" situation as the
xenotransplantation. XNAs are supposed
to be produced by B-cells of the CD5+
subgroup [3, 9]. The production of these
natural anti-Gal XNAs in humans does not
seem to be suppressed by conventional
immunosuppressive medications (e.g.,
Cyclosporine A [CsA], tacrolimus, aza-
thioprine, mycophenolate mofetil,
steroids) [10]. The XNAs responsible for
HAR are of the IgM phenotype, which are
very potent in activating the classical path-
way ofthe complement cascade [7].
Although in the pig-to-primate (and
pig-to-human) models the HAR seems to
be primarily mediated via the classical
pathway of complement activation, the
alternative pathway also appears to con-
tribute to the development ofHAR mainly
in rodent models (e.g., guinea pig to rat)
[11]. The activation ofthe alternative path-
way may be important in the ischemia-
reperfusion injury of the xenograft in the
pig to primate models [11].
The activation ofthe complement and
the binding ofXNAs result in the destruc-
tion of the endothelial cells [11, 12]. The
XNAs lead to the activation ofendothelial
cells (Type 1 activation, i.e., without gene
activation), the natural anticoagulants
heparan sulphate and ecto ADP-ase are
lost from the endothelial surface. These
changes, together with the products of
complement activation, may participate in
the resulting microthrombus formation [4,
5]. The organ is finally destroyed by the
consequent processes of interstitial oede-
ma, thrombosis, and hemorrhage. The
development of thrombosis seems to be
associated with a shift of the coagulation
system in the procoagulant direction: the
efficacy of anticoagulant factors decreas-
es, whereas the activity of procoagulant
mediators increases. Molecular incompati-
bilities between different species may be
important in this regard, since some anti-
coagulant factors do not work effectively
across species barriers (e.g., porcine
thrombomodulin does not effectively acti-
vate human protein C [13]; the porcine tis-
sue factor pathway inhibitor does not ade-
quately neutralize human factor Xa [14]),
on the other hand the activity of certain
procoagulant factors may even be
enhanced (e.g., enhanced potential of
porcine von Willebrand factor to associate
with human platelet GPIb [15]). The coag-
ulation and thrombotic disorders partici-
pate in the later phases of the rejection
process as well, and may even manifest
themselves in such systemic and life-332 Igaz: Overcoming hyperacute rejection in xenotransplantation
threatening forms as thrombotic thrombo-
cytopenic microangiopathic state and dis-
seminated intravascular coagulation [16].
Since the endothelium is the primary
target ofHAR, it is important to note, that
tissues that do not have endogenous ves-
sels, e.g., pancreatic islets are not prone to
the destruction by HAR [17, 18].
The prolonged presence of a trans-
planted xenograft (if HAR could be avert-
ed) can enhance the titers of XNAs
belonging to theIgGphenotype, that -on
the otherhand - seemtoparticipate in the
processes of the DXR. In addition to
endothelial cells, these IgG anti-Gal anti-
bodies also bind to epitopes on fibroblasts,
chondrocytes, macrophages, basement
membranes, and extracellular matrix [19].
The interaction ofanti-Gal antibodies with
these epitopes may participate in the
development of a fibrotic response that is
feared to present a severe chronic compli-
cation of xenograft rejection. The incuba-
tion ofrenal fibroblasts with anti-Gal anti-
bodies resulted in increased transforming
growth factor i and collagen synthesis
[20]. The natural IgG anti-Gal antibodies
appear to display polyreactivity, i.e. they
were found to be reactive to DNA, actin,
myosin, and tubulin, in addition to the
Galal-3Gal structures [21]. This finding
may relate to a much broader physiologi-
cal importance of these antibodies, since
these natural, polyreactive antibodies are
surmised to be important in maintaining
immune homeostasis.
There are several possible ways to
prevent HAR. These can be divided in two
Table 1. Summary ofthe techniques aimed atthe prevention of hyperacute rejection.
Inhibiting the interaction of XNAs with the xenoantigens
Recipient Donor
1. Eliminating the XNAs from the 1. Infusion of a-galactosidase
recipient's circulation: plasmapheresis,
immunoadsorption, perfusion via
porcine organs (kidney, liver)
2. Infusion of Galal-3Gal oligosaccharides 2. Transfection of a-galactosidase
3. Anti-idiotype antibodies 3. Transfection of fucosyl-transferase
4. Accommodation (?)
5. Suppression of XNA-producing B-cells
6. Induction of tolerance (mixed chimerism,
gene therapy)
Inhibiting the activation of complement
Recipient Donor
1. Cobra venom factor 1. Transfection of human CRP
(MCP, DCF, CD59)
2. C1-inhibitor 2. Transfection of porcine CRPs
3. Soluble complement receptor 1Igaz: Overcoming hyperacute rejection in xenotransplantation 333
groups: methods influencing the recipients
(i) and the donors (ii). In both groups, the
main targets of intervention are the XNAs
(and their antigens recognized) and the
complement system. The treatment of the
donors seems to be the safer and more
convenient way. Table 1 summarizes the
currently available strategies aimed at the
prevention ofHAR.
STRATEGIESTOTREATTHE
RECIPIENT
The XNAs can be removed from the
circulation by various methods, e.g., by
plasmapheresis, perfusion via
immunoaffinity columns or swine organs
(e.g., liver, kidney). In a discordant pig to
baboon heart transplantation model, HAR
could be effectively prevented by an
immunoabsorption technique [22]. The
main problem related to these techniques
is that they result only in a temporal
diminution of XNA levels, and the anti-
body titers recur quickly. In patients who
received ABO (blood group) incompatible
transfusion, thephenomenon ofaccommo-
dation was described, i.e. the temporary
removal of the antibodies prevents HAR,
and later, despite the return ofthe antibod-
ies, no rejection occurs. Various mecha-
nisms are supposed to participate in the
genesis of accommodation, among these
the masking of xenoantigens, changes in
XNA affinity, or alterations in the gene
expression of endothelial cells may be
important. It may be surmised that a simi-
lar phenomenon may be useful in the pre-
vention ofHAR in xenotransplantation [7,
23]. In vitro data, however, do not unam-
biguously support this assumption.
In a rodent model of discordant
xenotransplantation (transplantation of
hamster hearts to presensitized rat recipi-
ents) a phenomenon similar to accommo-
dation was observed. By using cobra
venom factor (CVF) and CsA, HAR could
be prevented, and later, by keeping anti-
donor antibody levels low (by blood
exchange, CVF, and CsA), HAR did not
occur despite the later reappearance of
XNAs. DXR, however, later evolved. The
surviving hearts showed increased expres-
sion of protective genes (e.g., Bcl-2, Bcl-
XL,A20, HO-1) in endothelial and smooth
muscle cells, and a predominant intragraft
Th2 response [24].
Another approach is to treatrecipients
with haptens like Galccl-3Gal, to inhibit
the antigen-antibody reaction between the
XNAs and the cellular antigens [25]. Anti-
idiotype antibodies may also be applied to
reduce thebinding ofXNAs [26]. The sup-
pression of XNA-producing B-cell popu-
lations by anti-anti-Gal anti-idiotype anti-
bodies is also being investigated [26].
The activity of the human comple-
ment system can be suppressed by various
medications. CVF is (i) too toxic, because
it leads to the generation of C3a and C5a,
(ii) it is strongly antigenic, (iii) it loses its
effectivity in afew days, (iv) it may lead to
the elevation of anti-Gal antibody titers,
probably in association with the presence
of Gal epitopes in the structure of CVF
[27]. The Cl-inhibitor was found to be
active in inhibiting the activation of the
complement system in in vitro experimen-
tal models, especially when coadminis-
tered with heparin [28]. The application of
soluble complement receptor 1 (sCRI)
seems to be quite encouraging [29].
An alternative approach to prevent
HAR (and later rejection processes) by
treating the recipient appears to be the
induction oftolerance mechanisms toward
donor cells. By inducing tolerance mecha-
nisms, long-lasting acceptance of the
transplanted organs may be achieved. The
production of anti-Gal antibodies can be
inhibited if the immune cells (both T- and
B-cells) of the recipient are made tolerant
toward Galal-3Gal epitopes [30, 31]. The
most convenient way of tolerance induc-
tion is the generation of mixed chimerism
by the introduction of donor hemopoietic334 Igaz: Overcoming hyperacute rejection in xenotransplantation
cells to the recipient. To achieve this, host
conditioning regimens are needed to
deplete donor-reactive host T-cells.
Various protocols, e.g., total body irradia-
tion, cytotoxic drugs, and antibodies
against costimulatory molecules, can be
applied to promote the successful implan-
tation of donor stem cells. Since the natu-
rally occurring XNAs would destroy
infused xenogeneic bone marrow cells, the
XNAs should be removed from the circu-
lation prior to the infusion of the donor
bone marrow [32]. By introducing donor
bone marrow to the conditioned recipient
the state of mixed chimerism can be
achieved, where both donor and recipient
hemopoietic cells can be found in the
patient's bone marrow, and the newly
developing T-cell repertoire is tolerant
toward both donor and host cells. In a
murine model of discordant xenotrans-
plantation, by introducing Galal-3Gal
expressing donor cells to Galal-3Gal
knockout mice, the production of anti-Gal
antibodies could be inhibited through the
generation of mixed chimerism [33].
Galal-3Gal knockout mice are homozy-
gous for a targeted disruption of the al,3-
galactosyl-transferase gene, therefore they
do not express the Galcxl-3Gal epitope,
and produce anti-Gal antibodies similar to
primates [33]. Galal-3Gal knockout mice
harboring mixed chimerism were shown to
accept Galal-3Gal expressing heart
xenografts [34].
The establishment of mixed
chimerism in the pig-to-primate experi-
mental system seems to be more problem-
atic. Sablinski et al. managed to achieve
long-term survival of pig bone marrow
cells in cynomolgus monkeys by including
pig cytokines (stem cell factor and inter-
leukin-3) in the therapeutic regimen
besides the immunosuppressive medica-
tion (CsA and 15-deoxyspergualin) [35].
Considering thatthe induction oftolerance
is supposed to be related to the successful
homing and differentiation of donor anti-
gen-presenting cells in the recipient thy-
mus to induce deletion of donor-reactive
host cells, molecular incompatibilities
between porcine and human adhesion
molecules may be ofprimary significance.
Studies performed to date examining the
interactions between integrins, intercellu-
lar adhesion molecule-1 and CD44
showed thatthese molecules could interact
with their ligands across the species barri-
er [36, 37]. It should be noted, however,
that the introduction of animal bone mar-
row to a human recipient raises several
questions including infectological and eth-
ical problems, and the appearance ofgraft
versus host disease (host tissue destruction
by donor immune cells) cannot be exclud-
ed either.
To avoid the need for animal bone
marrow cells, investigations are also
aimed at the inhibition ofXNA production
by gene therapy. By introducing the
enzyme al,3-galactosyl-transferase to
autologous bone marrow cells of Galal-
3Gal knockout mice by retroviral gene
therapy, Galal-3Gal epitopes become
expressed on transfected cells. The expres-
sion of Galal-3Gal epitopes rendered the
mice tolerant toward these antigens and
the production of anti-Gal XNAs ceased
[38]. The presence of the transfected gene
could be regarded as molecular
chimerism. By this protocol the need for
xenogeneic bone marrow transplantation
could be avoided. However, it should also
be taken into account that in contrast to the
whole bone marrow transplantation only a
few antigens can be introduced by the
gene therapy, therefore the individual
would only be rendered tolerant to a
minority of antigens relevant in rejection
processes.
STRATEGIESTOTREATTHE
DONOR
It should be noted that recent data
show that HAR does not invariably appearIgaz: Overcoming hyperacute rejection in xenotransplantation 335
in discordant xenotransplantation models.
By increasing the donor organ size and
weight (in a kidney transplantation model)
the frequency of HAR could be reduced.
This phenomenon may be linked to the
immunoabsorption of the preformed anti-
bodies by the larger grafts without signifi-
cant damage to the organ as a whole [39].
A great advantage of xenotrans-
plantation versus allotransplantation can
be the fact that the donor of xenotrans-
plantation is known long before the opera-
tion and, therefore, it can be modulated to
promote the successful implantation ofthe
graft. Molecular biological techniques are
known for the genetic manipulation of
pigs, and several approaches are being
tried to prevent HAR in the recipient.
Considering that the techniques for
cloning pigs from somatic cells have only
been described recently [40, 41], and suc-
cessful gene knockout experiments in pigs
have not yet been performed, up to now
indirect methods were used for the
diminution or elimination of the anti-
Galal-3Gal response. The enzyme that
degrades Galul-3Gal, ax-galactosidase can
be transfected to pigs. A more promising
approach is the transfection of alpha-1,2-
fucosyl-transferase that uses the same sub-
strate as galactosyl-transferase (i.e., N-
acetyllactosamine), so by an elevated level
of fucosyl-transferase the expression of
Galal-3Gal can be reduced, due to a com-
petitive mechanism [26, 42].
The Galal-3Gal epitopes can also be
removed by enzymatic treatment, but this
appears to be a temporary solution,
because following their removal, the mol-
ecules will be soon regenerated [43].
Nevertheless the enzymatic treatment of
pig organs shortly before transplantation
can be regarded as a useful subsidiary
treatment.
Another possible approach to prevent
HAR is based upon the phenomenon of
homologous restriction of complement
activation. It is known for decades that the
complementO-mediated cytolysis is not
efficient when the complement and the tar-
get cells are of the same species, a phe-
nomenon called homologous restriction
[7]. Recent investigations shed light on the
mechanism of homologous restriction. It
turned out that the protein inhibitors of
complement activation (complement regu-
latory proteins: MCP [membrane cofactor
protein, CD46], DAF [decay acceleration
factor, CD55], and CD59) act in a species-
specific manner. Therefore, the theory
emerged that by introducing human com-
plement regulatory proteins (CRP) to
swine, HAR can be inhibited. Indeed, by
generating transgenic pigs for human
CD59 and DAF, HAR can be prevented in
baboons transplanted with these modified
pig organs [12, 44, 45]. The inhibition is
more effective if multiple transgenes are
present. Nevertheless, these organs are still
susceptible to DXR, which eventually
leads to their destruction. In cynomolgus
monkeys transplanted with transgenic
porcine organs transfected with human
DAF, survival of nearly 80 days was
observed by applying a combined
immunosuppressive strategy (splenecto-
my, CsA, cyclophosphamide, steroids)
[46].
The complement-inhibiting properties
of MCP and DAF can be combined in a
chimeric recombinant protein that turned
out to be effective in an in vitro model of
pig to human heart transplantation [47].
Recent data, however, cast doubt on
the unambiguous validity of homologous
restriction. Several research groups found
that swine CRPs can efficiently inhibit
human complement activation. MCP [40]
and CD59 [49-51] inhibited the activation
of the human complement cascade in a
similar extent as their human counterparts
did. By up-regulating CD59 expression on
porcine endothelial cells by treatment with
a Galal-3Gal binding lectin, the cells
could be made resistant to the deleterious
effects of human complement activation336 Igaz: Overcoming hyperacute rejection in xenotransplantation
[52]. Therefore it can be surmised that not
the human CRPs themselves but their
overexpression in the modified organs is
responsible for the inhibition of human
complement activation, and it is possible
that the overexpression of swine CRPs
would be equally effective.
PROBLEMS ASSOCIATED WITH
THETECHNIQUES AIMED ATTHE
PREVENTION OF HAR
A major problem with the elimination
of anti-Galal-3Gal antibodies in the
recipient and Galal-3Gal epitopes of the
donor is associated with the possible pro-
tective role of the antibodies against cer-
tain infections. Not only bacteria, but also
some viruses ofanimal origin bear Galal-
3Gal epitopes in their membranes (that
derive fromthe infectedcells ofthe animal
host). The anti-Gal XNAs are supposed to
participate in the complement-mediated
lysis ofenvelopedviruses. Ifthe graft does
not express Galal-3Gal, the viruses that
bud off from the cellular membranes of
such modified organs will also lack this
antigen, thus the XNAs would be ineffec-
tive against them [2, 8, 53].
One of the most important possible
dangers linked to xenotransplantation is
considered to be the infectious concern.
Among the infectious agents, viruses are
the most feared [2, 54]. At least 1 percent
ofthe mammalian genome is composed of
endogenous retroviruses [55]. The majori-
ty ofthese is presumed to be defective, but
there are experimental data that primate,
and unfortunately porcine endogenous
retroviruses as well, may infect human
cells [56].
Although Galal-3Gal is thoughtto be
the major xenoantigen in HAR, other anti-
gens may also be important, and these
could have pronounced roles in the rejec-
tion processes if Galal-3Gal has been
eliminated [57]. There are some data in
rodent models concerning the importance
of these alternative antigens. Removal of
Galal-3Gal epitopes in mice by galacto-
syltransferase knockout and fucosyltrans-
ferase transfection techniques leads to the
presentation of additional epitopes (e.g.,
the Forsmann antigen) that may also
induce a xenogeneic immune response
[42]. A further question concerns the
swine endothelium: by reducing the
expression of Galal-3Gal, other, previ-
ously hidden antigens will be exposed that
could lead to further complications. It can
also be supposed that the Galal-3Gal
molecules may be important in the func-
tioning ofthe pig endothel, and by remov-
ing them, we could interfere with the nor-
mal development ofpig organs.
Since some human CRPs are known
to be the receptors ofviruses, e.g., MCP is
the receptor for measles virus [58], DAF
for ECHO and Coxsackie viruses [59-61],
the transfection of human CRPs may ren-
der pig organs susceptible to human viral
infections. The infection of CD46 trans-
fected pigs with measles virus could inter-
fere with the cellular differentiation of the
organs. Recent investigations have shown
that the CRPs may also be important in the
activation of immune cells, and by intro-
ducing human CRPs to pigs the inhibition
ofHAR may be followed by enhanced cel-
lular rejection mechanisms. DAF is the
ligand of CD97 that is expressed on acti-
vated leukocytes [62]. Human CD59 was
found to exert costimulatory activity on
human T cells acting through CD2 [63].
By using porcine CRPs these problems
could be averted. In addition to the use of
porcine CRPs, other methods may also be
applied to circumvent the problem ofgraft
virus susceptibility. In the case of CD46,
by molecular remodeling techniques,
CD46 variants without measles receptor
activity are being developed that at the
same time seem to be even more potent
than wild-type CD46 in inhibiting human
complement activation [64]. A further
problem may be related to the possibilityIgaz: Overcoming hyperacute rejection in xenotransplantation 337
that by overexpressing CRPs (either
human or porcine) the enveloped viruses
released from the transfected porcine
organs may carry these CRPs in their
envelopes, thereby, they may be rendered
resistant to the attack of human comple-
ment [63].
A serious concern may be related to
the physiology of the transgenic animals.
Will the organs (and the animals them-
selves) differentiate and function properly,
as their wild-type counterparts? This con-
cern may be most pronounced in associa-
tion with the techniques that reduce the
Galal-3Gal expression. In fact, mice with
inactivated galactosyl-transferase genes
appear to develop normally, but develop
eye cataracts [65].
CONCLUDING REMARKS
Significant progress has been made in
recent years concerning the understanding
of the molecular mechanisms underlying
the pathogenesis of hyperacute rejection.
Numerous methods can bepotentially use-
ful to avert this formidable barrier to
xenotransplantation. Among these, the
techniques applying the genetic modifica-
tion of the donor animals appear to be the
most promising. The recent success ofpig
cloning could contribute to considerable
advances in the investigation ofxenotrans-
plantation. Nevertheless, serious problems
may be associated with some of these
methods. The infectious concern seems to
be the most significant. Careful investiga-
tions are required before these techniques
may enter the field ofclinical medicine.
It should be noted that by averting
HAR, further immunological barriers
appear. Among these delayed xenograft
rejection (DXR) seems to be the most
important, since unacceptably high levels
of chronic nonspecific immunosuppres-
sion would be needed to inhibit its pro-
gression. XNAs play central roles in the
pathogenesis of DXR as well, but the
described techniques that seem to be
appropriate for the elimination ofHAR do
not appear to be sufficient for the preven-
tion ofDXR. Since the prevention ofHAR
can be considered as possible, at present,
DXR seems to present the most formida-
ble obstacle in the way of successful
xenotransplantation. al,3-galactosyl-
transferase knockout pigs could be the
solution for the prevention of both HAR
and DXR. Other problems (e.g., physio-
logical) may also severely impede the
application ofxenotransplantation to solve
the current organ shortage.
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